Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.

The company posted adjusted earnings of $2.62 per share, beating market estimates of $1.98 per share. The company’s sales came in at $2.804 billion versus expectations of $2.632 billion.

Biogen narrowed its FY2026 adjusted EPS guidance from $15.85-$16.85 to $15.95-$16.75.

Biogen shares fell 0.3% to $243.34 in pre-market trading.

These analysts made changes to their price targets on Biogen following earnings announcement.

• Needham analyst Ami Fadia maintained the stock with a Buy and raised the price target from $256 to $290.
• Baird analyst Brian Skorney maintained the stock with an Outperform rating and raised the price target from $250 to $290.

Considering buying BIIB stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.